Siemens Healthineers Caught in a Perfect Storm as Sector Weakness and Domestic Austerity Collide

Siemens Healthineers hits 52-week low of €33.62 as GE HealthCare's earnings miss, German healthcare reforms, and tariff costs weigh on the stock.

Investors in Siemens Healthineers are staring at a grim reality: the stock has tumbled to levels not seen in six years, touching €34.00 on Wednesday before sliding further to a fresh 52-week low of €33.62 on Thursday. The sell-off has erased roughly 24% of the company's market value since the start of the year, and the pain shows no signs of letting up.

The immediate trigger came from across the Atlantic. GE HealthCare, a key US rival, saw its shares plunge by more than 14% after reporting disappointing quarterly earnings and slashing its full-year outlook. The company now expects adjusted earnings per share of $4.80 to $5.00, down from its previous forecast of $4.95 to $5.15, citing $250 million in additional costs from rising prices for memory chips, energy, and transportation. The market quickly concluded that Siemens Healthineers faces similar headwinds, sending its stock into a tailspin despite no negative news from the German group itself.

But the GE shock is only one piece of a much larger puzzle. Back home, the German cabinet approved a sweeping healthcare reform package on Wednesday aimed at plugging the deficit in the country's statutory health insurance system. The plan targets €20 billion in savings by 2027, with more than 40% of that sum falling directly on hospitals. For Siemens Healthineers, whose core business revolves around high-end imaging systems and laboratory diagnostics, this is a direct threat. German clinics are already postponing capital expenditure, and the uncertainty is weighing heavily on the stock.

The company is also grappling with its own operational challenges. Management has flagged around €400 million in additional costs from US tariffs this year, along with negative currency effects of up to €250 million. In China, an anti-corruption campaign has slowed demand in the diagnostics division, dragging down first-quarter revenue and putting pressure on adjusted earnings per share. Despite all this, the board has maintained its full-year guidance, targeting comparable revenue growth of five to six percent and adjusted earnings per share of €2.20 to €2.40.

Barclays analyst Hassan Al-Wakeel remains cautiously optimistic, keeping an "Overweight" rating and a €55 price target on the stock. He noted that GE HealthCare's imaging business actually beat revenue expectations, suggesting that the cost issue — not demand — was the real culprit. Whether Siemens Healthineers can absorb similar cost pressures better than its US rival will become clearer on May 7, when the company reports its second-quarter results.

Adding to the uncertainty is a structural shift in the company's ownership. Siemens AG, the parent group, plans to distribute its remaining 30% stake in Healthineers to its own shareholders — but not until the annual general meeting in February 2027, later than many investors had hoped. Once completed, the spin-off will remove a critical safety net: Siemens currently guarantees up to €13.9 billion in debt for its medtech subsidiary. After the separation, Healthineers will have to refinance that massive liability on its own, fundamentally altering its capital structure.

For now, the technical picture offers little comfort. The relative strength index (RSI) has fallen to around 28, signaling that the stock is deeply oversold. But with the German healthcare reform, tariff pressures, China headwinds, and a looming spin-off all converging at once, a sustained recovery may require more than just a bounce from oversold levels. All eyes are now on the May 7 earnings report to see whether management can deliver the positive catalyst that investors desperately need.